You are here: Industry Insights > Lilly

News List

Tackling dementia - Multipronged collaboration can accelerate progress Lilly
June 28, 2017
This article comes from Laura Campo, Advisor - International Corporate Affairs, Alzheimer's disease at Eli Lilly and Company
Lilly's galcanezumab significantly reduces number of migraine headache days cphi-online
June 14, 2017
Eli Lilly has announced positive results from three Phase III studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, including late-breaking data on several key secondary endpoints for galcanezumab compa
Lilly bolsters diabetes assets with $55m KeyBioscience deal pharmafile
June 12, 2017
Lilly bolsters diabetes assets with $55m KeyBioscience deal
Ensuring Universal Access is a Political Choice lilly
May 18, 2017
In the spirit of open debate, this blog represents the views of its author and her organization, EPF.
Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab lilly
May 15, 2017
Eli Lilly announced galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint in three Phase 3 studies.
Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications lilly
May 11, 2017
Insurance industry veteran will lead Lilly public affairs and lobbying efforts
Our Tax Code is Stuck in the '80s lilly
May 03, 2017
Not everything vintage is worth saving, especially when it comes to tax reform.
Lilly Declares Second-Quarter 2017 Dividend lilly
May 02, 2017
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2017 of $0.52 per share on outstanding common stock.
Lilly Reports First-Quarter 2017 Results lilly
April 26, 2017
First-quarter 2017 revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products.
Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progressi lilly
April 25, 2017
The Phase 3 study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in patients with HR+, HER2- advanced breast cancer

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page